MDGL FY 2018 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$96,000

Operating Income

-$40M

Net Income

-$33M

EPS (Diluted)

$-2.22

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$485M

Total Liabilities

$8M

Stockholders' Equity

$477M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$96,000	-$77,000	-24.7%
Operating Income	-$40M	-$32M	-26.9%
Net Income	-$33M	-$31M	-5.3%